Ellex Medical Lasers Limited
(ASX:ELX) has been granted FDA approval by China for its complete portfolio of glaucoma, vitreous floaters and secondary cataract treatment lasers.
Ellex calls these products, collectively, its ‘YAG laser’ portfolio. The FDA approval means all ophthamoloists in China can now access Ellex’s YAG laser portfolio, which the medical tech company says will likely lead to increased sales in the 2017 financial year.
The company says that China accounts for 80% of its sales in the Asian market.
The company also says that sales in Asia rose by 52% during the half year ended 31 December 2015.
Ellex reported a net profit of $1.17 million at 31 December 2015.
